E. Gómez de la Fuente , F.J. Ortiz de Frutos , M. Bergón Sendín , G. Melé Ninot
{"title":"Survey of Usual Clinical Practice in Patients With Chronic Spontaneous Urticaria Treated With Omalizumab Regarding the Management of Antihistamines","authors":"E. Gómez de la Fuente , F.J. Ortiz de Frutos , M. Bergón Sendín , G. Melé Ninot","doi":"10.1016/j.ad.2025.104549","DOIUrl":"10.1016/j.ad.2025.104549","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104549"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Peñuelas Leal , J.A. Peñuelas Ruiz , Á. González García , L. Bagan , C. Labrandero Hoyos , A. Grau Echevarría , V. Zaragoza Ninet , G. Pérez Pastor , L. García Fernández , M. Linares Barrios , D. Blaya Imbernon , M. Finello , E. Perez Zafrilla , E. Diez Recio , M. Marti Cabrera , J. Bagan , V. Alegre De Miquel
{"title":"Oral Roflumilast for Long-term Management of Behçet Spectrum Disorders: A Multicenter Observational Analysis","authors":"R. Peñuelas Leal , J.A. Peñuelas Ruiz , Á. González García , L. Bagan , C. Labrandero Hoyos , A. Grau Echevarría , V. Zaragoza Ninet , G. Pérez Pastor , L. García Fernández , M. Linares Barrios , D. Blaya Imbernon , M. Finello , E. Perez Zafrilla , E. Diez Recio , M. Marti Cabrera , J. Bagan , V. Alegre De Miquel","doi":"10.1016/j.ad.2025.104561","DOIUrl":"10.1016/j.ad.2025.104561","url":null,"abstract":"<div><h3>Background</h3><div>Recurrent aphthous stomatitis (RAS) and Behçet's disease (BD) are part of the Behçet spectrum disorders (BSD), sharing genetic traits and characterized by recurrent ulcers. No systemic treatment is approved for RAS or incomplete BD, despite significant quality-of-life impacts.</div></div><div><h3>Objective</h3><div>To evaluate the efficacy of roflumilast, a PDE4 inhibitor, in BSD patients and compare responses between RAS and BD.</div></div><div><h3>Methods</h3><div>This analytical observational study included a total of 33 patients with BSD (22, RAS; 11, BD) from 5 Spanish centers, followed over 52 weeks. Data were collected retrospectively and prospectively, assessing flare-ups, ulcers, pain, and duration. Statistical models compared outcomes across treatment periods.</div></div><div><h3>Results</h3><div>Roflumilast significantly reduced all studied response variables, with no loss of long-term efficacy. Differences between RAS and BD were minimal and clinically irrelevant. Adverse events occurred in 63% of patients, mostly mild and self-limiting, with tolerability improved through dose adjustments. Two patients (6.25%) dropped out due to adverse events.</div></div><div><h3>Conclusion</h3><div>Roflumilast is effective for managing BSD, offering a safe option to address unmet needs in RAS and BD. Its favorable safety profile and long-term efficacy support its use in the routine clinical practice.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104561"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J.F. Silvestre-Salvador , S. Santos-Alarcón , A. Mengual-Sendra , V. Zaragoza-Ninet , M.P. Ortega-García , M. Rodriguez , E. Monte-Boquet , R.F. Ruiz de Apodaca , N. Pérez Prior , F.J. Miquel-Miquel , J. Borras-Blasco
{"title":"Long-term Persistence, Safety and Efficacy Profile of Dupilumab in Atopic Dermatitis: A Real-world Retrospective Multicenter Study From Spain","authors":"J.F. Silvestre-Salvador , S. Santos-Alarcón , A. Mengual-Sendra , V. Zaragoza-Ninet , M.P. Ortega-García , M. Rodriguez , E. Monte-Boquet , R.F. Ruiz de Apodaca , N. Pérez Prior , F.J. Miquel-Miquel , J. Borras-Blasco","doi":"10.1016/j.ad.2025.104563","DOIUrl":"10.1016/j.ad.2025.104563","url":null,"abstract":"<div><h3>Background</h3><div>The safety and efficacy profile of dupilumab in the management of atopic dermatitis (AD) are established in clinical trials. However, long-term real-world persistence data in Spain are limited.</div></div><div><h3>Objective</h3><div>The primary endpoint of the study was to assess the 4-year persistence of dupilumab in routine clinical practice in patients with moderate-to-severe AD. Secondary endpoints included the analysis of safety and efficacy profile during the same period of time.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of dispensation registries and health records from 5 hospitals. Adults with moderate-to-severe AD starting on dupilumab treatment were followed for 4-years. Dupilumab persistence was estimated using Kaplan–Meier analysis. Efficacy was measured by changes in EASI and IGA scores. Significant adverse events (AEs) leading to discontinuation were recorded.</div></div><div><h3>Results</h3><div>A total of 251 patients included (mean age, 46 years; 59.4%, men; 64.5% with at least 1 atopic comorbidity; mean time from AD diagnosis, 14.5 years). Of these, 196 (78.1%) had been on ≥2 systemic therapies before starting dupilumab. Baseline EASI and IGA values averaged 27.9 and 4.0, respectively. Persistence rates were 90%, 80%, 78%, and 73% after 1, 2, 3, and 4-years, respectively. By 16 weeks, 47.8% and 54.7% of patients achieved EASI ≤3 or IGA ≤1, increasing to 76.3% and 77.2% by 52 weeks, and reaching 90.9% in the group followed for >3 years. A total of 38 patients (13.5%) discontinued dupilumab, mainly due to inefficacy (5.6%) and AEs (1.2%).</div></div><div><h3>Conclusion</h3><div>Dupilumab effectively reduced AD severity within the first few weeks, with most patients achieving mild/minimal disease activity or complete clearance by year 1. The observed safety profile was consistent with known data. High persistence rates up to 4-years suggest satisfaction with dupilumab long-term safety and efficacy profile in managing moderate-to-severe AD.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104563"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}